Poster Viewing Sessions
More information will follow.
Four poster viewing sessions are organized during the 32nd Annual Meeting.7
More information about the schedule will follow soon.
Thursday, 21 November 2024
| 12:30 - 13:30 | Poster Viewing Session I | |
| 17:15 - 18:15 | Poster viewing II |
Friday, 22 November 2024
| 10:00 - 10:30 | Poster Viewing Session III | |
| 13:00 - 14:00 | Poster viewing IV |
During those sessions, our Young Investigators, ECF Fellows and Investigators will present their posters to the jury onsite. E-posters will be also available for consultation on the ECF website.
The winners of the 3 Young Investigators Awards (one Award per category) will be announced on Friday, 10 November 2023 from 17:20 - 17:30.
The winners will also present their posters during the Young Investigators Awards presentations which will be held on Saturday, 11 November 2023 from 10:30 - 11:00.
| Hour Location |
Title | Location |
|---|---|---|
|
12:30 - 13:30 |
Poster Viewing Session I - Clinical + Epidemiology |
|
| -- |
ID 2: MACSiMiSE-BRAIN: a multi-centre randomised placebo controlled clinical trial Anna-Victoria De Keersmaecker |
|
| -- |
ID 11: Assessing the risk of relapse after in vitro fertilization in women with MS Marie Mainguy |
|
| -- |
ID 21: Social Outcomes as a Measure of Recovery in Patients with Early Onset MS Julian Lui |
|
| -- |
ID 23: Teriflunomide adherence in multiple sclerosis Vincent van Pesch |
|
| -- |
ID 30: Cognitive Correlates of Apathy in Multiple Sclerosis: an 8-year longitudinal study Mariachiara Gaita |
|
| -- |
ID 31: Premature thymic involution in MS and other autoimmune diseases Wein-Na Jin |
|
| -- |
ID 33: Does MSWS-12, patient-reported outcome of walking ability, mirror ataxic symptoms? Lina Anderhalten |
|
| -- |
ID 35: A CASE OF TUMEFACTIVE MULTIPLE SCLEROSIS Sofia Ntymenou |
|
| -- |
ID 36: RADIOLOGICALLY ISOLATED SYNDROME: A DIAGNOSTIC AND THERAPEUTIC CHALLENGE Sofia Ntymenou |
|
| -- |
ID 37: Cancer risk in MS: a 10-year nationwide study Chloé Pierret |
|
| -- |
ID 38: PRIMUS: Reusing research data as decision support for precision medicine in MS Stanislas Demuth |
|
| -- |
ID 44: Phase 3 REMODEL I/II Trials: Efficacy, Safety & Tolerability of Remibrutinib in RMS Xavier Montalban |
|
| -- |
ID 47: Remibrutinib’s Safety Across Immune-Mediated Diseases Supports Development in MS Xavier Montalban |
|
| -- |
ID 54: TRACK-MS: A new test to detect cognitive impairment in different subtypes of MS Ms Daniela Taranu |
|
| -- |
ID 60: Epidemiological Trends and Disease Burden of Multiple Sclerosis from 1990 to 2019 Sara Samadzadeh |
|
| -- |
ID 61: MOGAD Patient Spectrum: Insights from a Turkish Single-Center Study Abdulkadir Tunç |
|
| -- |
ID 62: Fenebrutinib in multiple sclerosis–results from the phase II FENopta study Prof Dr Amit Bar-Or |
|
| -- |
ID 65: Validation of protein-MS associations by Mendelian randomisation in a large cohort Shannon Bernard Healey |
|
| -- |
ID 67: Late Onset Multiple Sclerosis, Clinical Characteristics of a Mexican Group Diana Gomez |
|
| -- |
ID 69: Decoding cognitive dysfunction in multiple sclerosis: role of brainstem atrophy Eline Van Doninck |
|
| -- |
ID 71: Progressive multiple sclerosis: identifying distinct cognitive-affective profiles Angela Boschetti |
|
|
17:15 - 18:15 |
Poster Viewing Session II - Treatment + Investigations Part 1 |
|
| -- |
ID 10: Circadian rhythm and interferon safety in multiple sclerosis Dr Mehdi Maghbooli |
|
| -- |
ID 15: Safety and Efficacy of Tolebrutinib in RMS Participants: 3-Year Results Dr Jiwon Oh |
|
| -- |
ID 16: MRI Outcomes from the LTS Study of Tolebrutinib in RMS Participants: 3-Year Results Dr Jiwon Oh |
|
| -- |
ID17: Real-life outcome of teriflunomide treatment and its predictors in RRMS patients Hongmei Tan |
|
| -- |
ID 20: FATIGUE IS REDUCED DURING TREATMENT WITH DIMETHYL FUMARATE IN MULTIPLE SCLEROSIS Louise Moelgaard |
|
| -- |
ID 26: Health-related effects in multiple sclerosis during functional training Charlotte Klump |
|
| -- |
ID 27: Phase 3 trials of evobrutinib in relapsing MS: Design and baseline characteristics Xavier Montalban |
|
| -- |
ID28: Long term (5-year) efficacy and safety of evobrutinib in patients with relapsing MS Xavier Montalban |
|
| -- |
ID34: Effect of Evobrutinib on Vitality, Mental Health, and Fatigue in relapsing MS Prof Patrick Vermersch |
|
| -- |
ID 40: Patient preference and real-world outcomes of diroximel fumarate therapy in RRMS Angela Guerra |
|
| -- |
ID 41: SISTER – Subcutaneous: Observational study on TYSABRI® Patient Preference Angela Guerra |
|
| -- |
ID 42: Remibrutinib Ameliorates CNS Autoimmune Disease - Insights From EAE Virginia DeLasHeras |
|
| -- |
ID 43: Remibrutinib Inhibits Neuroinflammation Driven by B cells and Myeloid Cells in EAE Virginia DeLasHeras |
| Hour Location |
Title | Location |
|---|---|---|
|
10:00 - 10:30 |
Poster Viewing Session III - Basic Studies |
|
| -- |
ID 5: The immunometabolic landscape of bone marrow cells in multiple sclerosis Caiyun Qi |
|
| -- |
ID 6: The influence of dopamine on the monocyte-induced Th17-immune response in MS Dr Mikhail Melnikov |
|
| -- |
ID 7: IRAK-M suppresses microglial NLRP3 inflammasome activation and pyroptosis in EAE Bingtian Xu |
|
| -- |
ID 8: Reduced Aβ amyloid deposits relate to inflammation & neuronal survival in MS cortex Dr Jonathan Pansieri |
|
| -- |
ID 9: Myelopoiesis and its therapeutic implication in multiple sclerosis Kaibin Shi |
|
| -- |
ID 12: Physiological & inflammation induced aging impairs human oligodendroglial function Ms Farina Windener |
|
| -- |
ID 13: APOE Bearing Astrocytic Extracellular Vesicles Alleviates NMOSD Xindi Li |
|
| -- |
ID 14: Connexin hemichannel blockade ameliorates EAE by suppressing glial inflammation Ezgi Ozdemir Takase |
|
| -- |
ID 24: CSF CHIT1 predicts disability progression and reflects microglia activation in MS Stijn Swinnen |
|
| -- |
ID 45: Halting Brain Inflammation and Degeneration by Antagonizing FPR1 Fu-Dong Shi |
|
| -- |
ID 51: Immunoglobulin Deposition in the Progressive Multiple Sclerosis Spinal Cord Andrew Lockhart |
|
| -- |
ID 53: Aberrant iron deposition in the MS spinal cord relates to neurodegeneration Dr Marco Pisa |
|
| -- |
ID 58: Anodal tDCS promotes remyelination in the cuprizone model Ms Elena Rossi |
|
| -- |
ID 59: Candidate MS progression associated genes in human stem cell-derived neural models Mollie McKeon |
|
| -- |
ID 73: Transcorneal Electrical Stimulation modulates visual function in vivo Dr Valerio Castoldi |
|
|
13:00 - 14:00 |
Poster Viewing Session IV - Treatment + Investigations Part 2 |
|
| -- |
ID 46: An evidence based Global MS Patient Charter created by a multi-stakeholder alliance Pauline Gieseler |
|
| -- |
ID 48: Retrospective data analysis of a German cladribine cohort from MS treatment centres Michael Ernst |
|
| -- |
ID 50: Evoked potentials to predict rehabilitation outcome in progressive MS Alessandro Gradassi |
|
| -- |
ID 56: Extended interval dosing with ocrelizumab in multiple sclerosis Dr Frederik Novak Stenstad |
|
| -- |
ID 57: Treatment switch from OFA to OCR in RMS: Two case reports Tanja Maler |
|
| -- |
ID 63: Myelin PET imaging of cervical spinal cord is associated with disability in MS Milena Pitombeira |
|
| -- |
ID 64: Lymphopenia in DMF: Are there characteristics that can predict its occurrence? Diana Gomez |
|
| -- |
ID66: Vulnerability of thalamic nuclei at CSF interface during the entire course of MS Dr Ismail Koubiyr |
|
| -- |
ID 68: Reference FLAIR lesion volumes for the follow up of MS patients Annemie Ribbens |
|
| -- |
ID 70: EEG markers of cognitive involvement in MS: Event-Related Potentials to the SDMT Marta Tacchini |
|
| -- |
ID 72: Remote digital Symbol-Digit Modalities Test in pwMS: Validity and Reliability Mr Michelangelo Dini |
|
|
13:00 - 14:00 |
Poster Viewing Session I - Clinical + Epidemiology |
|
| -- |
ID 52: Longitudinal MRI structural and cognitive measures in MOGAD and MS Dr Valentina Camera |
|
|
17:20 - 17:30 |
Announcement Young Investigator Award Winners |
| Hour Location |
Title | Location |
|---|---|---|
|
10:30 - 11:00 |
Young Investigator Awards |